PMID- 32080337
OWN - NLM
STAT- MEDLINE
DCOM- 20201230
LR  - 20210219
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Feb 20
TI  - Assessment of adverse events related to anti-influenza neuraminidase inhibitors 
      using the FDA adverse event reporting system and online patient reviews.
PG  - 3116
LID - 10.1038/s41598-020-60068-5 [doi]
LID - 3116
AB  - The recommended antiviral drugs available for the treatment and prevention of 
      influenza are neuraminidase inhibitors (NAIs). The aim of this study was to 
      evaluate age-related clinical manifestations of adverse events (AEs) related to 
      NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the 
      analysis were oseltamivir, peramivir, zanamivir, and laninamivir. 
      Disproportionality was analyzed using the proportional reporting ratio (PRR), the 
      reporting odds ratio (ROR), and the information component (IC) methods. In total, 
      16729 AEs from 4598 patients and 575 AEs from 440 patients in the FAERS and 
      WebMD, respectively, were included in the analysis. In the FAERS, AEs were more 
      common among those who were younger (<19 years) for zanamivir, while for those 
      who were older (>65 years) for peramivir. A disproportionality analysis showed 
      that signals for vomiting and hallucinations were detected in younger patients 
      given oseltamivir, while an abnormal hepatic function, cardiac failure, shock, 
      and cardio-respiratory arrest were detected in older patients given peramivir. 
      Psychiatric disorders were most common in younger and older patients, while 
      gastrointestinal disorders were most common in adult given oseltamivir in the 
      WebMD. Adverse symptoms related to NAIs varied and depended on the drugs used and 
      the age of the patient.
FAU - Han, Nayoung
AU  - Han N
AD  - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul 
      National University, Seoul, Republic of Korea.
FAU - Oh, Jung Mi
AU  - Oh JM
AUID- ORCID: 0000-0002-1836-1707
AD  - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul 
      National University, Seoul, Republic of Korea. jmoh@snu.ac.kr.
FAU - Kim, In-Wha
AU  - Kim IW
AD  - College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul 
      National University, Seoul, Republic of Korea. iwkim2@hanmail.net.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200220
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Acids, Carbocyclic)
RN  - 0 (Antiviral Agents)
RN  - 0 (Guanidines)
RN  - 0 (Pyrans)
RN  - 0 (Sialic Acids)
RN  - 20O93L6F9H (Oseltamivir)
RN  - B408IW3GL5 (laninamivir)
RN  - EC 3.2.1.18 (Neuraminidase)
RN  - L6O3XI777I (Zanamivir)
RN  - QW7Y7ZR15U (peramivir)
SB  - IM
MH  - Acids, Carbocyclic/adverse effects
MH  - Adolescent
MH  - Adult
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiviral Agents/*adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Guanidines/adverse effects
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Influenza, Human/*drug therapy
MH  - Internet
MH  - Male
MH  - Middle Aged
MH  - Neuraminidase/*antagonists & inhibitors
MH  - Odds Ratio
MH  - Oseltamivir/adverse effects
MH  - Patient Participation
MH  - Pyrans/adverse effects
MH  - Risk Factors
MH  - Sialic Acids/adverse effects
MH  - United States
MH  - United States Food and Drug Administration
MH  - Young Adult
MH  - Zanamivir/adverse effects
PMC - PMC7033147
COIS- The authors declare no competing interests.
EDAT- 2020/02/23 06:00
MHDA- 2020/12/31 06:00
PMCR- 2020/02/20
CRDT- 2020/02/22 06:00
PHST- 2019/08/07 00:00 [received]
PHST- 2020/02/07 00:00 [accepted]
PHST- 2020/02/22 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/12/31 06:00 [medline]
PHST- 2020/02/20 00:00 [pmc-release]
AID - 10.1038/s41598-020-60068-5 [pii]
AID - 60068 [pii]
AID - 10.1038/s41598-020-60068-5 [doi]
PST - epublish
SO  - Sci Rep. 2020 Feb 20;10(1):3116. doi: 10.1038/s41598-020-60068-5.